·|¡@¡@°T Á`´Á¼Æ¡G²Ä815´Á 2016¦~²Ä010´Á(105.03.14~105.03.18)~CAPA·|°T¤U¸ü~ ¬d Åç µn °O ¬Û Ãö °T ®§ ƒÜ ¥» ¶g °T ®§ 1. °]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ßq©ó105¦~3¤ë14¤é(¤@)¤U¤È15:00-16:00¡A°²ÂåÃÄ«~¬dÅ礤¤ß(¥x¥_¥««n´ä°Ï©¾§µªF¸ô¤»¬q465¸¹)¦a¤U¤G¼ÓC201·|ij«Ç¥l¶}¡u105¦~«×²Ä¤G¦¸²£©x¾Ç·¾³q·|ij¡v¡A¥»¤½·|¥Ñ¾Gµq¤¤¥D¥ô©eû¤Î³\¯¾¾ì°Æ¥D¥ô©eû¥Nªí¥X®u¡C 2. °]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ßq©ó105¦~3¤ë14¤é(¤@)¤U¤È16:00-17:00¡A°²TRPMA (¥x¥_¥««n´ä°Ï©¾§µªF¸ô¤»¬q465-1¸¹)¤@¼Ó·|ijÆU¥l¶}¡u°ê»Úªk³W¬ã°Q»¡©ú·|¡v¡A¥»¤½·|¥Ñ¼ï¨q¶³±`°È²z¨Æ¤Î¾Gµq¤¤¥D¥ô©eû¥Nªí¥X®u¡C 3. ½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p¬°¦¨¥ß°ê®aÃĪ«¼f¬d¤¤¤ß°t¦X×qÃĨƪk¯ó®×»¡©ú·|¡Aq©ó105¦~3¤ë16¤é(¤T)¤U¤È14:00¡A°²¹Ãĸp©ø¶§¤j¼ÓA701¤j§°ó¥l¶}¡A¥»¤½·|¥Ñ¼ï¨q¶³±`°È²z¨Æ¤Î¶À´fs¥Nªí¥X®u¡C 4. CAPA¡®TPADA ¬dÅçµn°O»Pªk³W©eû·|Áp®u·|ij©ó105¦~3¤ë18¤é(¤)¤U¤È15:00-17:00¡A°²¨â·|¦X¸p¿ì¤½·|ij«Ç(¥x¥_¥««Ø°ê¥_¸ô¤G¬q123¸¹3¼Ó)¥l¶}¡C 5. ªÀ¹Îªk¤H¤¤µØµLµß»s¾¯¨ó·|q©ó105¦~3¤ë18¤é(¤)09:30-17:00¡A°²»O¤j¾®ºA¬ì¾Ç¤¤¤ßº[ª«²z¾ÇÀ]°ê»Ú·|ijÆU(204«Ç)¥l¶}¡u¬ü°êÃĨå(USP)¾ÉŪ¬ã°Q·|¡v¡C ƒÜ ªñ ´Á °T ®§ 1. ªÀ¹Îªk¤H¤¤µØ¥Á°ê¾Ç¦WÃĨó·|©Ó±µ½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p105¦~«×¡u´£¤ÉÃÄ«~GMP/GDPºÞ²z¨î«×¹FPIC/S¼Ð·Ç¤§¬ã¨s¡v©e¿ìpµe¡A¸ÓpµeÀÀ©ó105¦~03¤ë24¤é(¥|)Á|¦æÃÄ«~GDP·~ªÌ»¡©ú·|¡A¥H¨Ñ¥DºÞ¾÷Ãö¤Î·~ªÌ·¾³q¤§¥¥x¡C 2. ¬°¥[±j¥~¬É¹ï©óÂåÀø¾¹§÷GDP¤§¤F¸Ñ¡A°]¹Îªk¤Hª÷Äݤu·~¬ã¨sµo®i¤¤¤ß¯S©ó105¦~3¤ë30¤éÁ|¿ì¡uÂåÀø¾¹§÷Àu¨}¬y³q³W½d±Ð¨|°V½mº[»¡©ú·|¡v(¸Ô¦pªþ¥ó)¡AÅwªï·|û¿ãÅD³ø¦W°Ñ¥[¡C 3. ªÀ¹Îªk¤H¥xÆW¥ÍÂå«~½è«OÃÒ¨ó·|±µ¨ü½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p©e°U¿ì²z¡uÃÄ«~Á{§É¸ÕÅç¬d®Ö»¡©ú·|(¤@)¡v¡Aq©ó105¦~3¤ë30¤é°²°ê¥ß¥xÆW¤j¾Ç¤½¦@½Ã¥Í¾Ç°| ¤½½Ã¤j¼Ó101Á¿°óÁ|¿ì(¸Ô¦pªþ¥ó)¡AÅwªï·|û¿ãÅD³ø¦W°Ñ¥[¡C 4. ªÀ¹Îªk¤H¤¤µØµLµß»s¾¯¨ó·|q©ó105¦~4¤ë8¡B15¡B22¤é¥l¶}¡uÃļtQC¹êÅç«Ç¹B§@¹ê°È¬ã°Q·|¡v(¸Ô¦pªþ¥ó)¡AÅwªï·|û¿ãÅD³ø¦W°Ñ¥[¡C 5. °]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ß±µ¨ü½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸ppµe©e°U¡A¨ó§U¬ãÀÀ½á§Î¾¯»P¥]¸Ë§÷®Æ¤§«~½èºÞ²z¬Fµ¦¤ÎÁ|¿ì¬ÛÃö¬ã°Q·|µ¥¡A¬°¼W¶i¹ï°ê»ÚÁͶջP¹ª«¤§¤F¸Ñ¡A±N©ó105¦~4¤ë26¤é¤U¤È14:00-17:00ÁܽЫn¥ú¤Æ¾Ç®}¤ßÄɸg²z¡A´N½á§Î¾¯¤§«~½èºÞ±±»P¥]§÷¬ÛÃöijÃD¶i¦æºtÁ¿¡A¥»¤½·|¥Ñ¼ï¨q¶³±`°È²z¨Æ¥Nªí¥X®u¡C 6. ªÀ¹Îªk¤H¤¤µØµLµß»s¾¯¨ó·|q©ó105¦~¤¤ë(¬K©u¯Z)¤Î¤E¤ë(¬î©u¯Z)¡A°²µLµß»s¾¯¨ó·|·|ij«Ç(¥x¥_¥«©Ó¼w¸ô¤@¬q35¸¹3¼Ó)¥l¶}¡u(105)ÃÄ«~GMP¤Jªù½Òµ{¡v(¸Ô¦pªþ¥ó)¡AÅwªï·|û¿ãÅD³ø¦W°Ñ¥[¡C ·| °È µo ®i ¬Û Ãö °T ®§ ƒÜ ªñ ´Á °T ®§ 1. ¥»·|©ó105¦~03¤ë23¤é(¤T)¤U¤È15:00-17:00¡A©ó¥»·|¿ì¤½·|ij«Ç(¥x¥_¥««Ø°ê¥_¸ô¤G¬q123¸¹3¼Ó)¥l¶}²Ä¤»©¡²Ä14¦¸±`°È²zºÊ¨ÆÁp®u·|¡A¥Ñ¯Î·½¤ô²z¨Æªø¤Î¶À©ú¸qºÊ¨Æ·|¥l¶°¤H¦@¦P¥D«ù¡C
°T ®§ Âà ª¾ ¡¯¤½·|¦¬¤å ½Ã¥ÍºÖ§Q³¡ µo¤å¤é´Á¤Î¤å¸¹¡G105.3.11/³¡±Â¹¦r²Ä1051100673¸¹ ¨ç ¥»¤½·|¦¬¤å105163¸¹(3¤ë) ¥D¦®¡G¡u¹«~·~ªÌ½Ã¥Í¦w¥þºÞ²zÅçÃҤΩe°UÅçÃÒºÞ²z¿ìªk¡v¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê105¦~3¤ë11¤é¥H³¡±Â¹¦r²Ä1051100670¸¹¥O¼o¤î¡Aµo¥¬¥O¤Îªþ¥ó½Ð¦Ü½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸pºô¯¸(http://www.fda.gov.tw)¤§¡u¥»¸p¤½§i¡vºô¶¤U¸ü¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.11/³¡±Â¹¦r²Ä1051100667¸¹ ¨ç ¥»¤½·|¦¬¤å105166¸¹(3¤ë) ¥D¦®¡G¡u¹«~½Ã¥Í¦w¥þºÞ²z¨t²ÎÅçÃÒ¾÷ºc»{ÃÒ¤ÎÅçÃÒºÞ²z¿ìªk¡v¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê105¦~3¤ë11¤é¥H³¡±Â¹¦r²Ä1051100664¸¹¥Oq©wµo¥¬¬I¦æ¡A¯÷ÀË°eµo¥¬¥O(§tªþ¥ó)¼v¥»1¥÷¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.10/½Ã³¡«O¦r²Ä1051260064C¸¹ ¨ç ¥»¤½·|¦¬¤å105172¸¹(3¤ë) ¥D¦®¡G¡u¥þ¥Á°·±d«OÀIÃĪ«µ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¡v³¡¤À±ø¤å¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê105¦~3¤ë10¤é¥H½Ã³¡«O¦r²Ä1051260064¸¹¥O×¥¿µo¥¬¡A¯÷ÀË°eµo¥¬¥O¼v¥»(§tªk³W©R¥O±ø¤å)1¥÷¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.16/³¡±Â¹¦r²Ä1051402132¸¹ ¨ç ¥»¤½·|¦¬¤å105175¸¹(3¤ë) ¥D¦®¡GÀË°e¡u¸¨¹ê±M§Q³sµ²¨î«×ÃĨƪkתk¤½Å¥·|¡v·|ij¬ö¿ý¤@¥÷¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü ½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p µo¤å¤é´Á¤Î¤å¸¹¡G105.3.14/ FDAÃĦr²Ä1051400051B¸¹ ¨ç ¥»¤½·|¦¬¤å105165¸¹(3¤ë) ¥D¦®¡GÀË°e¥»¸p¤½§i¡u105¦~«×ÃÄ«~¤£¨}«~¡]§tÀø®Ä¤£µ¥¡^¤Î¤ÆùÛ«~¤£¨}¨Æ¥ó¡]¥]¬A¤£¨}«~¤Î¤£¨}¤ÏÀ³¡^³q³ø¬ÛÃö·~°È¤§©e°U¾÷ºc¡v¡A½ÐÂા©ÒÄÝ·|û¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.15/ FDAÃĦr²Ä1051403158¸¹ ¨ç ¥»¤½·|¦¬¤å105169¸¹(3¤ë) ¥D¦®¡G¬ü°ÓÀq¨FªFÃļtªÑ¥÷¦³¤½¥q¥xÆW¤À¤½¥qÃÄ«~¡uªiÁɯS18²@§J/²@¤É¿@ÁY¿éª`²G¡APosanol 18mg/mL Concentrate for Solution for Infusion (½Ã³¡ÃÄ¿é¦r²Ä026570¸¹)¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü110¦~2¤ë22¤é¤î¡A½Ð ¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.16/ FDAÃĦr²Ä1051403167¸¹ ¨ç ¥»¤½·|¦¬¤å105173¸¹(3¤ë) ¥D¦®¡G¥xÆW塩³¥¸q»sÃĪѥ÷¦³¤½¥qÃÄ«~¡u·ç¨©¶ðÂIºwÀR¯ßª`®g²G¡ARAPIACTA for Intravenous Drip Infusion 300mg (½Ã³¡ÃÄ¿é¦r²Ä026649¸¹)¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü110¦~2¤ë19¤é¤î¡A½Ð ¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.16/ FDAÃĦr²Ä1051403168¸¹ ¨ç ¥»¤½·|¦¬¤å105174¸¹(3¤ë) ¥D¦®¡G·s¥[©Y°Ó²ö¤ó¨È¤Ó¦³¤½¥q¥xÆW¤À¤½¥qÃÄ«~¡u²bÀu©úá´¹ª`®g¾¯100LD50³æ¦ì¡AXeomin Powder for Solution for Injection 100 LD50 Units (½Ã³¡µß¬Ì¿é¦r²Ä000994¸¹)¡v¤Î¡u²bÀu©úá´¹ª`®g¾¯50LD50³æ¦ì¡AXeomin Powder for Solution for Injection 50 LD50 Units (½Ã³¡µß¬Ì¿é¦r²Ä000995¸¹)¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü110¦~2¤ë23¤é¤î¡A½Ð ¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.17/ FDAÃĦr²Ä1051403103¸¹ ®Ñ¨ç ¥»¤½·|¦¬¤å105178¸¹(3¤ë) ¥D¦®¡GÀË°e½ÃºÖ³¡105¦~3¤ë11¤é³¡±Â¹¦r²Ä1041408733¸¹¤½§i¼v¥»¤Î¡uÃÄ«~¦w©w©Ê¸ÕÅç°ò·Ç¡v×¥¿±ø¤å1¥÷(ªþ¥ó)¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.18/ FDAÃĦr²Ä1051403282¸¹ ¨ç ¥»¤½·|¦¬¤å105179¸¹(3¤ë) ¥D¦®¡G´¼Àº¥Í§Þ»sÃĪѥ÷¦³¤½¥qÃÄ«~¡u¦w¯à±o·L¯×Åéª`®g¾¯5²@§J/²@¤É(½Ã³¡ÃÄ¿é¦r²Ä026655¸¹)¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü109¦~12¤ë7¤é¤î¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.18/ FDAÃĦr²Ä1051403284¸¹ ¨ç ¥»¤½·|¦¬¤å105180¸¹(3¤ë) ¥D¦®¡G»OÆWªü´µ¯S±¶§Q±dªÑ¥÷¦³¤½¥qÃÄ«~¡u±¶´_¹çª`®g¾¯600²@§J(½Ã³¡ÃÄ¿é¦r²Ä026611¸¹)¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü109¦~12¤ë11¤é¤î¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.18/ FDAÃĦr²Ä1051403271¸¹ ¨ç ¥»¤½·|¦¬¤å105182¸¹(3¤ë) ¥D¦®¡G»´ä°Ó¦N¥ß¨ÈÂåÃĦ³¤½¥q¥xÆW¤À¤½¥qÃÄ«~¡u®L©^¹ç½¤¦ç¿õ¡AHarvoni tablets (½Ã³¡ÃÄ¿é¦r²Ä026675¸¹ )¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü109¦~12¤ë22¤é¤î¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü ½Ã¥ÍºÖ§Q³¡¤¤¥¡°·±d«OÀI¸p µo¤å¤é´Á¤Î¤å¸¹¡G105.3.11/°·«O¼f¦r²Ä1050035028¸¹ ¨ç ¥»¤½·|¦¬¤å105164¸¹(3¤ë) ¥D¦®¡GÀË°e105¦~2¤ë18¤é¥l¶}¤§¡u¥þ¥Á°·±d«OÀIÃĪ«µ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¦@¦PÀÀq·|ijÃÄ«~³¡¤À²Ä18¦¸(105¦~2¤ë)·|ij¬ö¿ý¡v¤A¥÷(¦pªþ¥ó)¡A½Ð¬d·Ó¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.15/°·«O¼f¦r²Ä1050035034¸¹ ¤½§i ¥»¤½·|¦¬¤å105176¸¹(3¤ë) ¥D¦®¡G¤½§i¼È¤©¤ä¥I§t·L¶q¤¸¯À¤§ÃÄ«~¡uAddamel N concentrate for solution for infusion (10mL/amp)¡v¡B¡uPeditrace concentrate for infusion solution (10mL/vial)¡v¤Î¡uAddaven concentrate for solution for infusion (10mL/amp)¡v¦@3«~¶µ¡C¡°¤½¨ç¤U¸ü µo¤å¤é´Á¤Î¤å¸¹¡G105.3.15/°·«O¼f¦r²Ä1050053535¸¹ ¤½§i ¥»¤½·|¦¬¤å105177¸¹(3¤ë) ¥D¦®¡G¤½§i¼È¤©¤ä¥I§tpanitumumab¦¨¤ÀÃÄ«~¡]¦pVectibix¡^¤Î¨äÃÄ«~µ¹¥I³W©w¡C¡°¤½¨ç¤U¸ü |